10-K: Biomerica Reports FY2026 Results, Faces Going Concern Doubt

Biomerica, Inc. filed its annual report for the fiscal year ended May 31, 2026, detailing a 16% revenue decline, continued operating losses, and significant concerns regarding its ability to continue as a going concern, though it secured additional financing and advanced product commercialization.

Summary

• Biomerica, Inc. reported net sales of $4.45 million for the fiscal year ended May 31, 2026, a 16% decrease from $5.31 million in the prior year.
• The company incurred a net loss of $3.78 million for fiscal year 2026, compared to a net loss of $4.97 million in fiscal year 2025.
• Operating expenses remained high, with Selling, General, and Administrative expenses increasing by 6% to $4.89 million, while Research and Development expenses decreased by 23% to $788,000.
• The company has substantial doubt regarding its ability to continue as a going concern, with cash and cash equivalents at $1.31 million as of May 31, 2026, insufficient to cover operating plans for the next 12 months.
• Biomerica raised approximately $1.83 million in net proceeds from its at-the-market (ATM) offering program during fiscal year 2026.
• The company received FDA clearance for its hp+detect test and advanced the commercialization of its inFoods IBS product, including securing a Medicare payment rate of $300.
• A significant corporate action was the amendment to increase authorized common stock from 25 million to 300 million shares, approved by stockholders in December 2025 and effective in June 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to continued operating losses, declining revenues, and substantial doubt about the company's ability to continue as a going concern, despite some positive developments in product commercialization and financing.

Positives

• The company secured approximately $1.83 million in net proceeds from its at-the-market (ATM) offering program during fiscal year 2026, providing additional liquidity.
• The inFoods IBS product received a national Medicare payment rate of $300, effective January 1, 2026, and initial claims have been paid at this rate.
• The hp+detect test received registration from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026 and secured its first commercial order.
• Research and development expenses decreased by 23% to $788,000, reflecting the transition of certain programs towards commercialization.
• Net cash used in operating activities improved by 11% to $3.42 million compared to the prior fiscal year.
• The company entered into a Master Services Agreement for CDMO services with initial target fees exceeding $1.75 million.
• Subsequent to year-end, the company completed a private placement raising approximately $2.23 million in gross proceeds.

Negatives

• Net sales decreased by 16% to $4.45 million in fiscal year 2026 from $5.31 million in fiscal year 2025.
• The company reported a net loss of $3.78 million for fiscal year 2026, compared to $4.97 million in fiscal year 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as its cash and cash equivalents are insufficient to fund operations for the next 12 months.
• Selling, General, and Administrative expenses increased by 6% to $4.89 million in fiscal year 2026.
• The company's backlog of unshipped orders decreased significantly from $1.32 million in May 2025 to $604,000 in May 2026.
• The company relies heavily on a few key distributors, with one accounting for 31% of net sales in both fiscal years 2025 and 2026.
• The company's stock price has been volatile and may continue to fluctuate unpredictably, with a risk of delisting from Nasdaq if the market value of listed securities falls below $5 million for 30 consecutive business days.

Risks

• The company has a history of operating losses and negative cash flows from operations, and there is no guarantee of future profitability or positive cash flows.
• The company's ability to continue as a going concern is dependent on obtaining additional financing, achieving operating efficiencies, increasing sales, and reducing costs.
• Operating results may fluctuate adversely due to factors outside the company's control, including regulatory clearances, competition, reimbursement changes, economic conditions, and international trade risks.
• The company faces risks related to its international sales, including economic fluctuations, regulatory changes, geopolitical instability, tariffs, and currency exchange fluctuations.
• The company relies on a limited number of key distributors that account for a substantial majority of its total revenue, and the loss of any key distributor could significantly impact sales.
• The company's intellectual property rights are critical, and risks include third-party infringement claims, misappropriation of proprietary rights, and the potential inadequacy of patent protection.
• The company needs to continue raising additional funds to finance future capital or operating needs, which could dilute existing stockholders' interests or lead to unfavorable terms.
• The company's business and products are highly regulated, and failures or delays in obtaining regulatory approvals, or changes in laws and regulations, could negatively affect operations.

Future Outlook

The company's future viability depends on the successful execution of its strategic plans, securing additional financing, and achieving profitable operations. Management believes current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months. Strategies include increasing sales, reducing expenses, selling non-core assets, and seeking additional debt or equity financing.

Management Comments

• Management believes our rapid point-of-care tests, when properly used, can be as accurate as laboratory tests.
• We continue to evaluate opportunities to manage costs, preserve liquidity and allocate resources toward initiatives that we believe have the greatest potential to create shareholder value.
• Management believes the establishment of the $300 Medicare payment rate for inFoods IBS represents an important step toward broader market access.
• Management believes our current cash and cash equivalents are insufficient to meet our operating cash requirements and strategic growth objectives for the next twelve months.

Industry Context

StockSavvy.ai notes that Biomerica operates in the highly competitive diagnostic products industry, facing established players with significantly greater resources. The company's focus on niche diagnostic-guided therapy products like inFoods IBS and hp+detect aims to address unmet clinical needs, but faces challenges in market adoption, reimbursement, and regulatory hurdles, particularly with evolving standards like the EU IVDR.

Comparison to Industry Standards

• The company's net sales of $4.45 million for FY2026 are significantly lower than those of larger, established diagnostic companies such as Abbott Laboratories (>$10 billion annual revenue) or Roche Diagnostics (>$15 billion annual revenue).
• Biomerica's R&D expenditure of $788,000 in FY2026 is a small fraction of the R&D budgets of industry leaders, which often exceed hundreds of millions or billions of dollars annually.
• The company's reported net loss and ongoing concerns about its ability to continue as a going concern contrast sharply with the profitability and financial stability of major players in the diagnostic sector.
• The development and commercialization timelines for Biomerica's products, such as inFoods IBS, appear longer and more resource-constrained compared to the rapid product launch cycles often seen from larger competitors with dedicated commercialization teams and substantial marketing budgets.

Management Changes

Legal Proceedings

• As of May 31, 2026, there were no pending legal proceedings.

Related Party Transactions

• On May 29, 2026, the company entered into a Securities Purchase Agreement to sell its investment in Diagnosis S.A. to its Chief Executive Officer and other purchasers for $500,000.
• In connection with the sale of Diagnosis S.A. investment, the company issued a secured promissory term note for $500,000 to its Chief Executive Officer.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances, continued operating losses, and risk of delisting from Nasdaq. However, recent capital raises and potential product commercialization offer upside.
• Employees: Continued uncertainty regarding the company's going concern status may impact job security and morale. However, the company continues to invest in R&D and commercialization efforts.
• Creditors: The company's going concern issues and reliance on external financing could impact its ability to meet debt obligations.
• Customers/Distributors: Continued reliance on a few key distributors poses a risk to sales stability. The company's ability to meet demand and maintain product quality is crucial.

Next Steps

• Continue phased commercialization of inFoods IBS product, focusing on gastroenterology physician practices.
• Advance reimbursement strategy for inFoods IBS, including pursuing private payer insurance companies.
• Pursue distribution, partnership, and licensing opportunities for inFoods IBS in the U.S. and internationally.
• Continue marketing hp+detect to laboratories in the U.S. and Europe and pursue broader commercial adoption.
• Continue to manage operating expenses and allocate resources toward commercialization, reimbursement, and revenue generation.
• Explore strategic opportunities to enhance and create shareholder value.
• File a registration statement for the resale of shares from the Private Placement within 30 calendar days of the Closing Date.

Key Dates

Recommendation

The company's continued operating losses, declining revenues, and substantial doubt about its ability to continue as a going concern present significant risks. While there are some positive developments in product commercialization and recent capital raises, these are not sufficient to outweigh the fundamental financial instability and operational challenges. The potential for dilution and delisting further supports a negative outlook.

Keywords

Biomerica, Diagnostic Products, inFoods IBS, hp+detect, Medical Devices, Biotechnology, SEC Filing, 10-K Report